Skip to main navigation Skip to search Skip to main content

Docetaxel (D)-ifosfamide (IF) combination in patients with metastatic hormone-refractory-prostate cancer (HRPC). A phase I study

    Activity: Talk or presentation › Conference presentation

    Description

    Contributors: Kellokumpu-Lehtinen Pirkko / Tieteelliset esitykset
    Period18 May 2002
    Event titleAmerican Society of Clinical Oncology (Thirty-Eight Annual Meeting)
    Event typeOther
    Degree of RecognitionInternational